U.S. markets open in 4 hours 14 minutes

Chemomab Therapeutics Ltd. (CMMB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3300-0.1400 (-5.67%)
At close: 04:00PM EDT

Chemomab Therapeutics Ltd.

Building 7
Kiryat Atidim
Tel Aviv 6158002
972 77 331 0156

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Dale R. Pfost Ph.D.Chairman & CEO192kN/A1957
Dr. Adi Mor George Ph.D.Co-Founder, Chief Scientific Officer & Exec. Director480kN/A1982
Mr. Donald R. Marvin MBACFO, Exec. VP & COO94kN/A1953
Barbara LindheimConsulting VP of Investor & PR, Strategic CommunicationsN/AN/AN/A
Dr. David M. Weiner M.D.Interim Chief Medical OfficerN/AN/A1965
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Corporate Governance

Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.